Developing a National Registry of Pharmacologic and Biologic Clinical Trials Workshop Report (2006) / Chapter Skim
Currently Skimming:
2 The Need for Clinical Trial Registries
2 The Need for Clinical Trial Registries
Pages 5-8
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 5... ...
report results of the trials. This information has many audiences: patients, health care providers, researchers, medical journal editors, pharmaceutical companies, health insurers, and regulators.
|
From page 6... ...
· Health care professionals need both unbiased summary infor mation derived from all trials conducted on a drug or therapy, and the capacity to look at the clinical data from any single study. They do not want to confine their review to the approved drug labeling or articles published in medical journals.
|
From page 7... ...
In striking a balance among these competing interests regarding the scope of clinical trial registries, an overriding goal is to sustain public trust in the integrity of clinical research and in the process for translating research into new drugs and biologics.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.